Start:
March 1, 2017
End:
May 2024
Enrollment:
160
This trial will test the safety and effectiveness of dronabinol (Marinol) to reduce agitation in older adults with Alzheimer's. Dronabinol is a synthetic form of an active ingredient in cannabis and is an approved medication to treat chemotherapy-related nausea and AIDS-related lack of appetite. In this Phase 2 trial, participants will take either a 5-mg dronabinol capsule or placebo twice daily the first week, and a 10-mg capsule or placebo twice daily for weeks two and three. Researchers will assess the safety and effectiveness of the medication on reducing symptoms of agitation and aggression.
Minimum Age: 60 Years
Maximum Age: 95 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Florida | |
---|---|
Miami Jewish Health
Miami,
FL
33137
Recruiting
Victoria Petrulla | |
Maryland | |
Johns Hopkins University
Baltimore,
MD
21224
Recruiting
Mersania Jn Pierre, B.A. | |
Massachusetts | |
McLean Hospital
Belmont,
MA
02478
Recruiting
Rosain Ozonsi, B.S. | |
Tufts Medical Center
Boston,
MA
02111
Recruiting
Todd Laffaye, B.A. | |
North Shore Medical Center
Salem,
MA
01970
Recruiting
Rosain Ozonsi, B.A. |
Lead: Johns Hopkins University
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT02792257
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health